IDEXX Laboratories Crescita futura
Future criteri di controllo 2/6
IDEXX Laboratories prevede che gli utili e i ricavi cresceranno rispettivamente di 9.8% e 7.6% all'anno. Si prevede che l'EPS crescerà di 10.8% all'anno. Si prevede che il ritorno sul capitale proprio sarà di 34.2% in 3 anni.
Informazioni chiave
9.8%
Tasso di crescita degli utili
10.8%
Tasso di crescita dell'EPS
| Medical Equipment crescita degli utili | 17.1% |
| Tasso di crescita dei ricavi | 7.6% |
| Rendimento futuro del capitale proprio | 34.2% |
| Copertura analitica | Good |
| Ultimo aggiornamento | 15 Nov 2024 |
Aggiornamenti recenti sulla crescita futura
Recent updates
At US$420, Is It Time To Put IDEXX Laboratories, Inc. (NASDAQ:IDXX) On Your Watch List?
Nov 19
IDEXX Laboratories Q3: Weak End-Market Demand Continues
Nov 11Investors Appear Satisfied With IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) Prospects
Oct 28Here's Why We Think IDEXX Laboratories (NASDAQ:IDXX) Is Well Worth Watching
Oct 15We Think IDEXX Laboratories (NASDAQ:IDXX) Can Manage Its Debt With Ease
Sep 18A Look At The Intrinsic Value Of IDEXX Laboratories, Inc. (NASDAQ:IDXX)
Sep 05What Is IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) Share Price Doing?
Aug 20IDEXX Laboratories Q2: Headwinds From Low U.S. Clinical Visits
Aug 12A Look Into IDEXX Laboratories' (NASDAQ:IDXX) Impressive Returns On Capital
Jul 02Looking For Fast Growth In Healthcare? IDEXX Has You Covered
Jun 28Here's Why IDEXX Laboratories (NASDAQ:IDXX) Has Caught The Eye Of Investors
Jun 04Should You Think About Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX) Now?
May 21IDEXX Laboratories, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
May 03What IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) P/E Is Not Telling You
Apr 27IDEXX Laboratories (NASDAQ:IDXX) Has A Rock Solid Balance Sheet
Apr 11IDEXX: Strong Recurring Revenues From Consumables, Software But Overvalued (Rating Downgrade)
Apr 08Is It Too Late To Consider Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX)?
Jan 30IDEXX Laboratories: Valuation Rerating Doesn't Seem Justified
Jan 16Here's Why IDEXX Laboratories (NASDAQ:IDXX) Has Caught The Eye Of Investors
Jan 15IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) Shareholders Might Be Looking For Exit
Dec 31IDEXX Laboratories (NASDAQ:IDXX) Seems To Use Debt Rather Sparingly
Dec 15Why IDEXX Laboratories, Inc. (NASDAQ:IDXX) Could Be Worth Watching
Oct 26Here's Why We Think IDEXX Laboratories (NASDAQ:IDXX) Is Well Worth Watching
Oct 10Is IDEXX Laboratories (NASDAQ:IDXX) Using Too Much Debt?
Sep 07Is It Time To Consider Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX)?
Jul 04These 4 Measures Indicate That IDEXX Laboratories (NASDAQ:IDXX) Is Using Debt Reasonably Well
May 31At US$484, Is IDEXX Laboratories, Inc. (NASDAQ:IDXX) Worth Looking At Closely?
Apr 05Here's Why IDEXX Laboratories (NASDAQ:IDXX) Can Manage Its Debt Responsibly
Feb 22Why IDEXX Laboratories, Inc. (NASDAQ:IDXX) Could Be Worth Watching
Jan 05Is IDEXX Laboratories (NASDAQ:IDXX) Using Too Much Debt?
Nov 24When Should You Buy IDEXX Laboratories, Inc. (NASDAQ:IDXX)?
Sep 20IDEXX Laboratories: Outstanding Business, But Valuation Is Key
Aug 15These 4 Measures Indicate That IDEXX Laboratories (NASDAQ:IDXX) Is Using Debt Reasonably Well
Aug 15IDEXX Laboratories Stock Is Very Expensive
Aug 08IDEXX Laboratories Non-GAAP EPS of $1.58 misses by $0.05, revenue of $860.55M misses by $1.57M
Aug 02Are IDEXX Laboratories, Inc. (NASDAQ:IDXX) Investors Paying Above The Intrinsic Value?
Jul 26Here's Why We Think IDEXX Laboratories (NASDAQ:IDXX) Might Deserve Your Attention Today
Jul 12Is It Time To Consider Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX)?
Jun 16IDEXX Laboratories: Great Business, But Still Overvalued
May 25Previsioni di crescita degli utili e dei ricavi
| Data | Ricavi | Guadagni | Flusso di cassa libero | Liquidità dell'operazione | Avg. Numero di analisti |
|---|---|---|---|---|---|
| 12/31/2026 | 4,532 | 1,103 | 1,067 | 1,224 | 9 |
| 12/31/2025 | 4,161 | 984 | 988 | 1,120 | 11 |
| 12/31/2024 | 3,882 | 875 | 867 | 1,133 | 9 |
| 9/30/2024 | 3,845 | 866 | 793 | 917 | N/A |
| 6/30/2024 | 3,785 | 846 | 839 | 969 | N/A |
| 3/31/2024 | 3,725 | 867 | 797 | 921 | N/A |
| 12/31/2023 | 3,661 | 845 | 773 | 907 | N/A |
| 9/30/2023 | 3,588 | 823 | 680 | 830 | N/A |
| 6/30/2023 | 3,514 | 791 | 593 | 747 | N/A |
| 3/31/2023 | 3,431 | 699 | 456 | 612 | N/A |
| 12/31/2022 | 3,367 | 679 | 384 | 543 | N/A |
| 9/30/2022 | 3,340 | 670 | 438 | 580 | N/A |
| 6/30/2022 | 3,309 | 664 | 429 | 578 | N/A |
| 3/31/2022 | 3,274 | 735 | 605 | 746 | N/A |
| 12/31/2021 | 3,215 | 745 | 636 | 756 | N/A |
| 9/30/2021 | 3,135 | 757 | 663 | 765 | N/A |
| 6/30/2021 | 3,047 | 728 | 694 | 770 | N/A |
| 3/31/2021 | 2,858 | 674 | 666 | 745 | N/A |
| 12/31/2020 | 2,707 | 582 | 540 | 648 | N/A |
| 9/30/2020 | 2,591 | 497 | 445 | 585 | N/A |
| 6/30/2020 | 2,475 | 460 | 366 | 524 | N/A |
| 3/31/2020 | 2,457 | 437 | 286 | 453 | N/A |
| 12/31/2019 | 2,407 | 428 | 304 | 459 | N/A |
| 9/30/2019 | 2,351 | 423 | 290 | 439 | N/A |
| 6/30/2019 | 2,291 | 407 | 274 | 418 | N/A |
| 3/31/2019 | 2,252 | 390 | 262 | 400 | N/A |
| 12/31/2018 | 2,213 | 377 | 277 | 400 | N/A |
| 9/30/2018 | 2,170 | 330 | 280 | 386 | N/A |
| 6/30/2018 | 2,117 | 307 | N/A | 386 | N/A |
| 3/31/2018 | 2,045 | 284 | N/A | 377 | N/A |
| 12/31/2017 | 1,969 | 263 | N/A | 373 | N/A |
| 9/30/2017 | 1,906 | 277 | N/A | 353 | N/A |
| 6/30/2017 | 1,862 | 263 | N/A | 343 | N/A |
| 3/31/2017 | 1,820 | 245 | N/A | 343 | N/A |
| 12/31/2016 | 1,775 | 222 | N/A | 339 | N/A |
| 9/30/2016 | 1,732 | 214 | N/A | 312 | N/A |
| 6/30/2016 | 1,690 | 202 | N/A | 289 | N/A |
| 3/31/2016 | 1,637 | 192 | N/A | 258 | N/A |
| 12/31/2015 | 1,602 | 192 | N/A | 222 | N/A |
| 9/30/2015 | 1,554 | 174 | N/A | 170 | N/A |
| 6/30/2015 | 1,531 | 182 | N/A | 186 | N/A |
| 3/31/2015 | 1,508 | 182 | N/A | 188 | N/A |
| 12/31/2014 | 1,486 | 182 | N/A | 236 | N/A |
| 9/30/2014 | 1,488 | 199 | N/A | 274 | N/A |
| 6/30/2014 | 1,443 | 193 | N/A | 259 | N/A |
| 3/31/2014 | 1,405 | 190 | N/A | 258 | N/A |
| 12/31/2013 | 1,377 | 188 | N/A | 246 | N/A |
Previsioni di crescita futura degli analisti
Guadagni vs tasso di risparmio: La crescita prevista degli utili di IDXX ( 9.8% all'anno) è superiore al tasso di risparmio ( 2.6% ).
Guadagni vs Mercato: Si prevede che gli utili di IDXX ( 9.8% all'anno) cresceranno più lentamente rispetto al mercato US ( 15.4% all'anno).
Guadagni ad alta crescita: Si prevede che gli utili di IDXX cresceranno, ma non in modo significativo.
Ricavi vs Mercato: Si prevede che il fatturato di IDXX ( 7.6% all'anno) crescerà più lentamente rispetto al mercato US ( 8.9% all'anno).
Ricavi ad alta crescita: Si prevede che il fatturato di IDXX ( 7.6% all'anno) crescerà più lentamente di 20% all'anno.
Previsioni di crescita dell'utile per azione
Rendimento futuro del capitale proprio
ROE futuro: Si prevede che il Return on Equity di IDXX sarà elevato tra 3 anni ( 34.2 %)